Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials

• Published in: Clinical journal of the American Society of Nephrology 2020-08, Vol.15 (8), p.1129-1138
• Main Authors: Shaman, Ahmed M, Smyth, Brendan, Arnott, Clare, Palmer, Suetonia C, Mihailidou, Anastasia S, Jardine, Meg J, Gallagher, Martin P, Perkovic, Vlado, Jun, Min
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antihypertensive Agents - adverse effects; Antihypertensive Agents - classification; Antihypertensive Agents - therapeutic use; Blood Pressure - drug effects; Comparative Effectiveness Research; Female; Humans; Hypertension - diagnosis; Hypertension - drug therapy; Hypertension - epidemiology; Hypertension - physiopathology; Kidney - physiopathology; Male; Middle Aged; Network Meta-Analysis; Original; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic - diagnosis; Renal Insufficiency, Chronic - epidemiology; Renal Insufficiency, Chronic - physiopathology; Renal Insufficiency, Chronic - therapy; Time Factors; Treatment Outcome
• ISSN: 1555-9041; 1555-905X; 1555-905X
• DOI: 10.2215/CJN.12201019

Elevated BP is an important risk factor for cardiovascular disease, with a prevalence of over 80% in patients undergoing maintenance dialysis. We assessed the comparative BP-lowering efficacy and the safety of BP-lowering drugs in patients undergoing maintenance dialysis. We performed a frequentist random effects network meta-analysis of randomized, controlled trials evaluating BP-lowering agents in adult patients undergoing maintenance dialysis. Electronic databases (CENTRAL, MEDLINE, and Embase) were systematically searched (up to August 2018) for relevant trials. The main outcome was systolic BP reduction. Forty trials (4283 participants) met our inclusion criteria. Angiotensin-converting enzyme inhibitors, -blockers, calcium-channel blockers, and aldosterone antagonists lowered systolic BP to a greater extent than placebo, with effect sizes ranging from -10.8 mm Hg (95% confidence interval, -14.8 to -6.7 mm Hg) for the aldosterone antagonists to -4.3 mm Hg (95% confidence interval, -7.2 to -1.5 mm Hg) for angiotensin-converting enzyme inhibitors. Aldosterone antagonists and -blockers were superior to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, and renin inhibitors at lowering systolic BP. Compared with angiotensin-converting enzyme inhibitors, aldosterone antagonists and -blockers lowered systolic BP by 6.4 mm Hg (95% confidence interval, -11.4 to -1.4 mm Hg) and 4.4 mm Hg (95% confidence interval, -7.4 to -1.3 mm Hg), respectively. Systolic BP reduction was not different with angiotensin receptor blockers, -blockers, and calcium-channel blockers compared with angiotensin-converting enzyme inhibitors. Renin inhibitors were less effective. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists incurred risks of drug discontinuation due to adverse events and hypotension. BP-lowering agents significantly reduced systolic BP in patients undergoing maintenance dialysis. -Blockers and aldosterone antagonists may confer larger reductions, although treatment with aldosterone antagonists may be limited by adverse events.